Replies to post #124180 on Biotech Values

[DewDiligence]

3Q11 Orencia sales were $233M (+27% YoY), of which $154M was in the US:

http://finance.yahoo.com/news/BristolMyers-Squibb-Delivers-bw-1217874273.html?x=0&.v=1

This is of some interest to MNTA investors insofar as MNTA may be working on an Orencia FoB for the US market.

FDA approval of the subcutaneous formulation of Orencia (#msg-65720598) occurred too late to have a material effect on the 3Q11 results.

All told, Orencia is doing pretty well for a drug that has been dismissed by many analysts as an also-ran. It is the clear leader in RA among non-TNFa biologics, easily outselling Rituxan and Actemra.